NINTEDANIB ZENTIVA 150 mg, soft capsule 60 capsules
Active ingredients: Nintedanib, Nintedanib esylate
Commercialized according to BDPMDispensing in France: Prescription only
Soft capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NINTEDANIB ZENTIVA 150 mg, capsule molle
- Pharmaceutical form
- capsule molle
- Route of administration
- orale
- Presentation description
- 60 plaquettes prédécoupées unitaires OPA : polyamide orienté aluminium PVC-Aluminium de 1 capsule(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 10 Apr 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66129469CIP73028681CIP133400930286814Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| NINTÉDANIBcapsule | 150 mg · une capsule | FT |
| ÉSILATE DE NINTÉDANIBcapsule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.